Industry News

Collaboration on Interferon Delivery System Announced

Published in Hepatitis Weekly, April 3rd, 2000

Viragen, Inc., Plantation, Florida, and Viragen Europe Ltd. have agreed to collaborate with Biosyntech applying a protein pharmaceutical delivery system.

The project will assess the potential of Biosyntech's BST-GEL as a sustained release system for Viragen's Omniferon, a natural, multi-subtype alpha interferon currently in Phase II clinical trials in Europe for hepatitis C.

Patients treated with interferon for hepatitis C typically receive three injections per week for approximately one year. Biosyntech's sustained release delivery system should potentially reduce the number of injections, reduce the costs, and maximize the compliance and potential...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2000-04-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry